Background Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF V600 -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAF V600 -mutant melanoma.
Introduction
Genetic alterations resulting in an activated MAPK pathway occur in almost all melanoma cases. The most frequent is the BRAF V600 mutation, which occurs in 35-50% of patients with a melanoma. 1 Activating BRAF mutations drive constitutive MAPK pathway activation, with subsequent proliferation and enhanced cellular survival, making BRAF kinase a promising therapeutic target. 1 In-vitro investigations have shown that growth of BRAF-mutated melanoma cells can be inhibited by BRAF or MEK inhibitors. 2 A crystallography-guided drug design approach produced several candidate ATP-competitive BRAFkinase inhibitors that were investigated in clinical trials. Vemurafenib was the first to show efficacy in BRAFmutant melanoma, 3, 4 followed by dabrafenib. 5 MAPK pathway reactivation is implicated in BRAF-inhibitor monotherapy resistance. 6 Additionally, toxic effects associated with BRAF inhibition, notably secondary squamous-cell skin cancer and other skin toxicities, are caused by BRAF inhibitors paradoxically activating the wild-type BRAF kinase, promoting dimerisation that triggers RAS-independent transactivation, and activation of the MAPK pathway in normal tissues. 7 Subsequent clinical trials [8] [9] [10] [11] in patients with BRAF V600 -mutant melanoma have shown that dual MAPK-pathway targeting with a BRAF inhibitor and a MEK inhibitor improves efficacy and ameliorates paradoxical MAPK activation-related toxic effects asso ciated with BRAFinhibitor monotherapy. Two BRAF-MEK inhibitor combinations (dabrafenib-trametinib and vemurafenibcobimetinib) are regarded as treatment options for metastatic or unresectable BRAF V600 -mutant melanoma in current guidelines. 12, 13 These BRAF-MEK inhibitor combinations are highly effective. However, both are associated with disease progression at approximately 12 months, and each combination causes different toxic effects in patients, highlighting the need for more effective and better tolerated therapies. [8] [9] [10] [14] [15] [16] [17] Encorafenib is an ATP-competitive BRAF inhibitor that suppresses the MAPK pathway in tumour cells that express several mutated forms of BRAF kinase (eg, V600E, V600D, and V600K mutations), with a more than 10-times longer dissociation half-life (>30 h) than either dabrafenib or vemurafenib, which enables sustained target inhibition. 18 Preclinical studies suggest that this property could enhance antitumour activity while reducing paradoxical activation of MAPK pathways in normal tissues. 18, 19 Binimetinib is an orally available, non-ATPcompetitive, allosteric inhibitor of MEK1 and MEK2. 20 Promising clinical activity and tolerability of the combination of encorafenib and binimetinib has been seen in patients with BRAF V600 -mutated melanoma in a phase 1b/2 and a phase 2 study. 21, 22 Furthermore, the maximum tolerated dose of encorafenib when combined with binimetinib was higher than the maximum tolerated dose of encorafenib monotherapy, thus allowing the use of a higher encorafenib dose when combined with binimetinib in subsequent trials. 22 Here, we describe the results of part one of the COLUMBUS trial, a phase 3 study of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with advanced BRAF V600 -mutant unresectable melanoma.
Methods

Study design and participants
COLUMBUS is a two-part, multicentre, randomised, open-label phase 3 study of the efficacy and safety of encorafenib plus binimetinib combination therapy
Research in context
Evidence before this study We searched for articles and abstracts during the development of this Article that were published in PubMed and Embase between Jan 1, 2014, and Dec 20, 2017. Search terms were comprehensive ("melanoma" + "treatment" + "phase" [all fields]; "encorafenib", "BRAF inhibition" + "melanoma" [all fields]). Selected abstracts were not limited to those in the English language and focused on phase 3 clinical trial data. Our search results indicated that a combination of available BRAF and MEK-pathway inhibitors provided additional benefit with reasonable tolerability in advanced melanoma compared with BRAF-inhibitor monotherapy. Preclinical and phase 1 and 2 clinical data suggested that the BRAF inhibitor encorafenib in combination with the MEK inhibitor binimetinib could further improve therapy for patients with BRAF-mutant melanoma.
Added value of this study
In this randomised trial in patients with BRAF-mutant melanoma, treatment with the combination of the BRAF inhibitor encorafenib 450 mg and the MEK inhibitor binimetinib 45 mg improved progression-free survival and overall response compared with encorafenib 300 mg or vemurafenib, with better tolerability. Furthermore, in what to our knowledge is the first controlled head-to-head comparison of BRAF-inhibitor monotherapy, encorafenib showed a progression-free survival advantage compared with vemurafenib. Additionally, the combination of encorafenib with binimetinib ameliorated toxic effects associated with encorafenib monotherapy, enabling the use of a higher dose of encorafenib. Consistent with preclinical findings, our results show that encorafenib monotherapy provides improved clinical efficacy compared with vemurafenib monotherapy, and that high-intensity, extended BRAF inhibition, in combination with MEK inhibition, could result in improved tumour control.
Implications of all the available evidence
Encorafenib in combination with binimetinib is a well tolerated and efficacious treatment option for BRAF-mutant metastatic melanoma. Overall survival data and long-term safety data will provide additional insights into the efficacy and tolerability of this combination. Additionally, our findings indicate that the combination of encorafenib with binimetinib has a different toxicity profile from other combinations of BRAF-MEK inhibitors, with low frequencies of pyrexia and photosensitivity.
versus vemurafenib or encorafenib monotherapy in patients with locally advanced unresectable or metastatic BRAF V600 -mutant melanoma. The study was originally designed to compare the efficacy of encorafenib 450 mg once daily plus binimetinib 45 mg twice daily with vemurafenib given at its clinically indicated dose, and with encorafenib given at 300 mg once daily (its maximum well tolerated dose as a monotherapy). However, because of a request from the US Food and Drug Administration (FDA), the study protocol was amended on Nov 4, 2014, and a new study phase (part two) was added to better understand and isolate the contribution of binimetinib to the combination by comparing encorafenib 300 mg plus binimetinib 45 mg against encorafenib 300 mg alone.
In part one of the study, patients were recruited at 162 hospitals in 28 countries, including 20 sites in North America, 124 sites in Europe, and 18 sites in other selected countries (appendix p 2-5). After completion of enrolment in part one, patients were recruited into part two of the study following the same eligibility criteria, and the combination of encorafenib at its monotherapy maximum tolerated dose plus binimetinib was compared with encorafenib monotherapy at the same dose. Part 2 was done to better characterise the contribution of binimetinib to the combination therapy, and the results will be published separately.
To be eligible, patients needed to be aged 18 years or older and meet the following criteria: have a histologically confirmed diagnosis of locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma (as per amendment 3; Nov 4, 2014); have the presence of a BRAF V600E or BRAF V600K mutation, or both, in their tumour tissue; have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; have adequate bone marrow, organ function (including cardiac function), and laboratory parameters (ie, absolute neutrophil count, haemoglobin concentration, platelet count, aspartate aminotransferase or alanine aminotransferase concentrations, and total bilirubin, creatinine, or calculated creatinine clearance); have evidence of at least one measurable lesion as detected by radiological or photographic methods according to guidelines based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; 23 and be treatment naive or have progressed on or after previous first-line immunotherapy (acceptable test limits for laboratory parameters are in the appendix, p 6). Key exclusion criteria included untreated CNS lesions; uveal or mucosal melanoma; known positive serology for human immunodeficiency virus, or an active hepatitis B or hepatitis C infection, or both; history of leptomeningeal metastases; a history of, current evidence of, or risk of retinal vein occlusion; Gilbert's syndrome; previous treatment with a BRAF or MEK inhibitor; previous systemic chemotherapy (as per protocol amendment 2 on Dec 22, 2013, and clarified in amendment 3 on Nov 4, 2014), extensive radiotherapy, or use of an investigational agent other than previous immuno therapy for locally advanced, unresectable, or metastatic melanoma (immunotherapy must have ended at least 6 weeks before randomisation); impaired cardiovascular function; uncontrolled arterial hyper tension; and neuromuscular disorders associated with high concentrations of creatine kinase. The full list of exclusion criteria is in the study protocol (appendix p 93).
Independent ethics committees or review boards at each study site approved the study protocol and amendments 1-4. Conduct of the study conformed with Good Clinical Practice guidelines and the ethical requirements outlined in the Declaration of Helsinki. Written informed consent was obtained from all patients before screening procedures were initiated.
Randomisation and masking
Patients were randomly allocated into one of the three treatment groups in the trial (1:1:1) to receive either encorafenib plus binimetinib (encorafenib plus binimetinib group), encorafenib (encorafenib group), or vemurafenib (vemurafenib group) by use of validated interactive response technology (Parexel International, Billerica, MA, USA). Randomisation was stratified by AJCC stage (IIIB, IIIC, IVM1a, IVM1b, or IVM1c), ECOG performance status (0 or 1), and BRAF-mutation status (BRAF V600E vs BRAF V600K ). After protocol amendment 2 (Dec 20, 2013), previous first-line immunotherapy (yes vs no) replaced BRAF-mutation status as a stratification factor. Investigators and patients were not masked to treatment assignment.
Procedures
Central genetic mutation analysis to ascertain the presence of BRAF mutations was done for all patients before enrolment with the bioMérieux THxID BRAF diagnostic test (bioMérieux, Marcy l'Etoile, France), which identifies both BRAF V600E and BRAF V600K gene mutations. Instances of previous immunotherapy were recorded for all patients. Patients received either encorafenib 450 mg orally once daily plus binimetinib 45 mg orally twice daily, encorafenib 300 mg orally once daily, or vemurafenib 960 mg orally twice daily according to randomised treatment assignment, and continued treatment until progression of disease per central review, death, unacceptable toxic effects, or withdrawal of consent. The type and frequency of clinical laboratory assessments are described in the appendix (p 10). Dose modifications, including treatment interruptions and dose reductions, were permitted for each of the drugs on the basis of tolerability and adverse events. Details regarding drug manufacture and permitted dose modifications are in the appendix (p 6).
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The relative dose intensity was defined as 100 × (the total cumulative dose a patient actually received while a on the study) divided by (the total cumulative dose a patient was scheduled to receive [ie, had they not had any dose adjustments or interruptions] while on the study).
Baseline imaging was done within 21 days of randomisation and included chest, abdomen, and pelvis MRI or CT, and brain MRI or CT to assess CNS disease. In the case of suspected bone metastases, a whole-body bone scan was done. Localised CT, MRI, or radiography was done for all skeletal lesions identified via the bone scan if not visible on the chest, abdomen, and pelvis CT or MRI. If clinically indicated, a CT or MRI scan was done of other areas of disease, as appropriate. Colour photographs were taken of all skin lesions, and lesion sizes were estimated with a metric ruler. Tumours were evaluated every 8 weeks during the first 24 months, and every 12 weeks thereafter, by use of the same imaging method as at baseline. Additional tumour assessments were done if progression was suspected by the treating physician. Tumour response was assessed centrally by blinded independent committee review and by local review according to guidelines based on RECIST version 1.1.
For safety assessments, we collected data on all adverse events; physical examinations such as specific ophthalmic and dermatological examinations, cardiac assessments (electrocardiogram and multiple-gated acquisition scan or echocardiogram); and clinical laboratory assessments. Because of the ocular-related toxicity profile of MEK inhibitors, all patients in the encorafenib plus binimetinib group had routine ophthalmic testing at each regularly scheduled visit during the treatment period. For patients in the encorafenib and vemurafenib groups, ophthalmic testing at each regularly scheduled visit was only required if retinal abnormalities were present at baseline. Details on the ophthalmological examinations are included in the appendix (p 6). The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events version 4.03. 24 We monitored adverse events during the study and for at least 30 days after the last dose of study drug.
The data cutoff date for analyses presented here was May 19, 2016. No interim analysis was done before the primary progression-free survival analysis presented in this Article. A data monitoring committee reviewed safety data approximately every 6 months.
Outcomes
The primary endpoint was the comparison of progressionfree survival in the encorafenib plus binimetinib versus vemurafenib groups as assessed by blinded independent central review. Progression-free survival was defined as the time from the date of randomisation to the date of the first documented disease progression or death from any cause, whichever occurred first. If a patient did not have a progression event at the time of the analysis cutoff or at the start of any new antineo plastic therapy, their data were censored at the date of last adequate tumour assessment. The key secondary endpoint was comparison of progression-free survival in the encoraf enib plus binimetinib group versus the encorafenib group. Other secondary endpoints included comparison of the progression-free survival of patients in the encorafenib group versus the vemurafenib group; best overall response (complete response, partial response, stable disease, progressive disease, or unknown, derived per RECIST version 1.1), overall response (proportion of patients with a best overall response of confirmed complete response or partial response), disease control (the proportion of patients with a best overall response of confirmed complete response, partial response, or stable disease [including patients with non-measurable disease]), duration of response (time from the date of first documented response [confirmed complete response or partial response] to the first documented progression or death due to melanoma), time to response (time between date of randomisation until first documented response of complete response or partial response), and safety of encorafenib plus binimetinib and encorafenib. Data from tumour assessments read by blinded independent central review were used for the primary and secondary endpoints and analysis of best overall response, duration of response, and disease control; data from local review were used in supportive analyses. Analyses of other secondary outcomes to be reported in a separate manuscript include overall survival, quality of life, resource utilisation, comparison of ECOG performance status, and pharmacokinetic analysis.
Statistical analysis
Sample size calculations were based on assumptions for progression-free survival medians derived from results of a phase 1b/2 study (NCT01543698) 22 for encorafenib plus binimetinib, a phase 1 study for encorafenib, 18 and updated results from the BRIM-3 25 and BRIM-2 26 / COMBI-v, 9 and coBRIM 14,27 trials for vemurafenib.
Analyses of the primary and key (type-I error controlled) secondary endpoints for part one of the study were event driven and done when patient enrolment in part one was complete and the prespecified number of progressionfree survival events for both the final primary and part one key secondary comparison were available. We used a hierarchical testing procedure to control type-I errors for the primary and key secondary endpoints. The key secondary endpoint of part one (progression-free survival of encorafenib plus binimetinib vs encorafenib) was to be tested if the primary efficacy endpoint (progression-free survival of encorafenib plus binimetinib vs vemurafenib) was significant. The driver of sample size was the key secondary endpoint of progression-free survival with encorafenib plus binimetinib versus encorafenib (as per amendment 3; appendix p 47); for this comparison, 191 progression-free survival events were required to detect a hazard ratio (HR) of 0·667 with 80% power by use of a log-rank test at a one-sided 2·5% level of significance. For the primary comparisons of encorafenib plus binimetinib versus vemurafenib, 145 progressionfree survival events were required to detect an HR of 0·58 with 90% power by use of a log-rank test at a one-sided 2·5% level of significance. Assuming that 15% of patients would be lost to follow-up, we estimated that 576 patients (192 in each group) would need to be recruited.
We analysed efficacy endpoints in the intention-to-treat population, which comprised all patients who had been randomised. Patients were analysed by treatment group and strata, as assigned during randomisation. Safety was analysed in all patients who received at least one dose of study drug and had at least one postbaseline safety assessment; patients were analysed according to the treatment they actually received. All data were used to the greatest extent possible without imputations for missing data (appendix p 7).
Median duration of follow-up for progression-free survival was estimated first, by summarising the observed follow-up for each patient (ie, the duration from date of randomisation to date of progression-free survival event or censoring), and second, through reverse Kaplan-Meier analyses. The reverse Kaplan-Meier median values are reported and reflect the potential follow-up in the absence of progressive disease or death. Progression-free survival was analysed according to the treatment group and two of the stratification factors (AJCC stage and ECOG performance status). Owing to the low expected prevalence of patients with previous immunotherapy (about 15%), for the stratified analyses it was prespecified that the two previous immunotherapy strata (yes vs no) were to be combined to avoid small or empty strata. Comparison of the distribution of progression-free survival used a stratified log-rank test (for the purposes of this summary, two-sided p values are reported). We presented the distribution of progression-free survival using the Kaplan-Meier method. We used stratified Cox regression models to estimate the HRs for progression-free survival, along with 95% CIs based on the Wald test. Sensitivity analyses were also prespecified. Prespecified sensitivity analyses examined different censoring rules, unstratified analyses, analyses of progression-free survival based on local tumour assessments, and analyses of the per-protocol population (appendix p 7). Subgroup analyses of baseline variables and potential prognostic factors, including previous immunotherapy, were also prespecified. We confirmed the proportional hazards assumption of the Cox models graphically with plots of log(−log[estimated survivor function]) versus log(time). We used the same methods for the key secondary comparison. We presented the overall response and disease control by treatment group with exact 95% CIs. Duration of response and time to response were estimated using Kaplan-Meier methodology. As part of the secondary outcome of encorafenib plus binimetinib and encorafenib safety, we summarised the time to first event using Kaplan-Meier methodology for several prespecified safety parameters. Median time to onset and 95% CIs were summarised, and we described other median values with 95% CIs or IQRs. We included nominal p values for secondary endpoints for descriptive purposes. SAS (version 9.2 or higher) was used for all analyses. This study is registered with ClinicalTrials.gov, number NCT01909453, and with EudraCT, number 2013-001176-38.
Role of the funding source
The study was sponsored and designed with input from the steering committee (RD, PAA, CR, and KTF) by Novartis until September, 2015, when sponsorship was transferred to Array BioPharma. Data were collected by Novartis and Array BioPharma during their respective sponsorships. Data were analysed by Array BioPharma's statistical team and interpreted by the study authors in collaboration with Array BioPharma. RD, PAA, CR, and KTF wrote the first draft of the report. Editorial support was funded by the study sponsor. RD, PAA, CR, and KTF had full access to all the data in the study, and had final responsibility for the decision to submit for publication.
Results
Between Dec 30, 2013, and April 10, 2015, 1345 patients were assessed, of whom 577 were enrolled and randomly assigned to a treatment group (192 to the encorafenib plus binimetinib group, 194 to the encorafenib group, and 191 to the vemurafenib group; figure 1 Median progression-free survival assessed by blinded independent central review was longer for patients in the encorafenib plus binimetinib group (14·9 months, 95% CI 11·0-18·5) than for those in the encorafenib (9·6 months, 7·5-14·8) or vemurafenib (7·3 months, 5·6-8·2) groups. Results of the per-protocol analyses were consistent (appendix p 12). Median progression-free survival by local review was similar: 14·8 months (95% CI 10·4-18·4) for the encorafenib plus binimetinib group, 9·2 months (7·4-12·9) for the encorafenib group, and 7·3 months (5·7-8·5) for the vemurafenib group (appendix p 23).
The primary comparison of progression-free survival by blinded independent central review of the encorafenib plus binimetinib versus vemurafenib groups showed a significant reduction in the risk of progression or death (HR 0·54, 95% CI 0·41-0·71; two-sided p<0·0001; figure 2A ). Progression-free survival by local review was similarly improved with encorafenib plus binimetinib versus vemurafenib (0·49, 0·37-0·64; two-sided nominal p<0·0001; appendix p 23). All subgroup analyses for the comparison of encorafenib plus binimetinib with vemurafenib showed point estimates in favour of the encorafenib plus binimetinib group, except for the presence of brain metastases at baseline, but this analysis included only nine patients in the encorafenib plus binimetinib group and three patients in the vemurafenib group ( figure 3) .
The key secondary comparison of progression-free survival by blinded independent central review showed a median of 14·9 (95% CI 11·0-18·5) months in the encorafenib plus binimetinib group and 9·6 (7·5-14·8) months in the encorafenib group (HR 0·75, 95% CI 0·56-1·00; two-sided p=0·051; figure 2B ). Progression-free survival by local assessment showed a larger treatment effect for the encorafenib plus binimetinib group than for the encorafenib group (0·68, 95% CI 0·52-0·90; two-sided nominal p=0·0064; appendix p 23). In other secondary endpoints, comparison of progression-free survival by blinded independent central review favoured the encorafenib group over the vemurafenib group (0·68, 95% CI 0·52-0·90; two-sided nominal p=0·0070); similar results were obtained by local assessment (appendix p 24).
A confirmed overall response by blinded independent central review occurred in 121 (63%) of 192 patients in the encorafenib plus binimetinib group compared with 98 (51%) of 194 patients in the encorafenib group and 77 (40%) of 191 patients in the vemurafenib group (table 2) . The confirmed overall response by local review had a similar pattern but was higher in each group than in the central review (table 2). The median time to response by blinded independent central review in responding patients corresponded to the time of the first assessment and was 1·8 months (95% CI 1·8-1·9) for the encorafenib plus binimetinib group, 1·9 months (1·9-1·9) for the encorafenib group, and 1·9 months (1·8-1·9) for the vemurafenib group. Median duration of confirmed objective response by blinded independent central review was 16·6 months (12·2-20·4) for the encorafenib plus binimetinib group, 14·9 months (11·1-not estimable) for the encorafenib group, and 12·3 months (6·9-16·9) for the vemurafenib group.
In the encorafenib plus binimetinib group, the median duration of treatment for each component of the HR 0·75 (95% CI 0·56-1·00); two-sided p=0·051 HR 0·54 (95% CI 0·41-0·71); two-sided p<0·0001 100 ] lists all grade 3-4 adverse events in the treatment groups; as per the study protocol, deaths were not graded and therefore were not included in table 3 ). Common adverse events reported more frequently in the encorafenib plus binimetinib group than in the encorafenib or vemurafenib groups (with a difference in proportion of patients of 10% or higher) were gastrointestinal toxic effects (diarrhoea, consti pation, vomiting, and abdominal pain), predominantly asymptomatic increases in creatine phosphokinase, and blurred vision. Common adverse events reported at a lower frequency (with a difference in proportion of patients of 10% or higher) in the encorafenib plus binimetinib group than in the encorafenib or vemurafenib groups were toxic effects to the skin (eg, pruritus, hyperkeratosis, rash, keratosis pilaris, palmoplantar keratoderma, palmoplantar erythro dysaesthesia syndrome, dry skin, skin papilloma, macro papular rash, and sunburn), alopecia, photosensitivity reaction, arthralgia, myalgia, pain in the extremities, decreased appetite, musculoskeletal pain, and decreased weight. 
0·54 (0·41-0·71)
Favours encorafenib plus binimetinib group
within the encorafenib plus binimetinib group than within the encorafenib or vemurafenib groups (appendix p 26). Similarly, fewer adverse events leading to treatment discontinuation occurred in patients in the encorafenib plus binimetinib group than in patients in the encorafenib or vemurafenib groups (appendix p 20). Time to discontinuation of treatment due to an adverse event was longer with encorafenib plus binimetinib than with encorafenib or vemurafenib (appendix p 26). Adverse events leading to discontinuation that were suspected to be related to study treatment occurred in 12 (6%) patients given encorafenib plus binimetinib, 19 (10%) given encorafenib, and 26 (14%) given vemurafenib (data not shown Toxic effects associated with BRAF and MEK inhibitors were further explored by grouping individually reported adverse events for similar clinical entities or pathophysiological processes. These events included pyrexia, rash, photosensitivity, secondary non-melanoma skin cancers (including squamous-cell cancer and basalcell carcinoma), serous retinopathy (including retinal pigment epithelial de tachment), left ventricular dysfunction, and abnormalities in liver function tests (appendix p 21). A toxic effect associated with the BRAF kinase inhibitor dabrafenib 9,17 -pyrexia (including increased body temperature, hyperpyrexia, and hyperthermia)-occurred in 35 (18%) of 192 patients in the encorafenib plus binimetinib group, 30 (16%) of 192 patients in the encorafenib group, and 55 (30%) of 186 patients in the vemurafenib group. Toxic effects to the skin, including rash, acneiform dermatitis, and palmoplantar erythrodysaesthesia syndrome, occurred less frequently in the encorafenib plus binimetinib group than in the encorafenib or vemurafenib groups. Photosensitivity, a toxic effect associated with the BRAF-kinase inhibitor vemurafenib, 10, 14 was seen in 56 (30%) patients in the vemurafenib group, nine (5%) patients in the encorafenib plus binimetinib group, and eight (4%) patients in the encorafenib group. Secondary non-melanoma skin cancers occurred infrequently. The most common were squamouscell cancers, in five (3%) patients in the encorafenib plus binimetinib group, 15 (8%) in the encorafenib group, and 32 (17%) in the vemurafenib group (appendix p 21). Specific MEK inhibitor toxic effects, including serous retinopathy and left ventricular dysfunction, were seen more frequently in the encorafenib plus binimetinib group than either the encorafenib or vemurafenib groups. Serous retinopathy occurred in 38 (20%) patients in the encorafenib plus binimetinib group, four (2%) patients in the encorafenib group, and three (2%) patients in the vemurafenib group. Most of the events in the encorafenib plus binimetinib group were grade 1 (23 [12%] of 192 patients) or grade 2 (ten [5%]), and resulted in dose interruption or adjustment in 11 (6%) patients but did not result in treatment discontinuations. Left ventricular dysfunction occurred in 15 (8%) patients in the encorafenib plus binimetinib group, four (2%) patients in the On-treatment deaths were due to disease progression in 11 (6%) patients in the encorafenib plus binimetinib group, 12 (6%) patients in the encora fenib group, and 17 (9%) patients in the vemurafenib group. None of the deaths due to adverse events were considered likely to be related to study treatment (appendix p 22), although there was one death in the combination group, which was considered possibly related to treatment by the investigator. This patient stopped treatment on study day 9 and died by suicide on day 24, 15 days after the last dose of study drug.
Discussion
In this phase 3, randomised trial in patients with BRAF-mutant melanoma, encorafenib plus binimetinib showed a favourable efficacy and safety profile compared with vemurafenib monotherapy. Progression-free survival in patients treated with encorafenib plus binimetinib was significantly longer than in those treated with vemurafenib, and progression-free survival results were consistent with those seen in previous trials using vemurafenib in this setting. 9, 10 The encorafenib plus binimetinib group had a median progression-free survival of 14·9 (95% CI 11·0-18·5) months while the encorafenib group had a median progression-free survival of 9·6 (7·5-14·8) months; (HR 0·75, 95% CI 0·56-1·00; twosided p=0·051; figure 2B ). More patients in the encorafenib plus binimetinib group attained an overall response compared with those in the encorafenib group (121 [63%; 95% CI 56-70] vs 98 [51%; 43-58]) Additionally, the tolerability profile of encorafenib plus binimetinib appeared to be more favourable than vemurafenib or encorafenib monotherapy, as reflected in the higher dose intensity achieved and the longer median exposure to treatment in the encorafenib plus binimetinib group than the monotherapy groups. The adverse event profile was also favourable, with fewer grade 3 or 4 toxic effects, fewer toxic effects requiring dose interruption or modification, a later time to onset of grade 3 or 4 adverse events, and fewer treatment discontinuations due to adverse events in the encorafenib plus binimetinib group than in the monotherapy groups. The mechanistic underpinnings of efficacy and safety for the various BRAF-MEK inhibitor combinations are probably based on the specific characteristics of the individual drugs. Encorafenib inhibits BRAF V600E kinase activity in a biochemical assay at similar concentrations as dabrafenib and vemurafenib. However, the dissociation half-life is longer than 30 h and much longer than those of dabrafenib (2 h) and vemurafenib (0·5 h), resulting in improved pharmacodynamics with longer-lasting pERK inhibition. 18 Furthermore, in BRAF V600 -mutant cell lines, encorafenib was more potent at inhibiting proliferation than dabrafenib or vemurafenib. 18 Previous studies suggest that the maximum monotherapy dose of encorafenib is 300 mg/day. 18 In combination with the MEK inhibitor binimetinib, however, the toxicity and overall tolerability of encorafenib when given as a monotherapy are substantially ameliorated. This amelioration allows the use of the higher dose of encorafenib (450 mg) in the combination treatment, thus potentially providing greater pathway inhibition that lasts longer than the monotherapy. 18 Consistent with these earlier results, this study confirmed the ability to safely increase the dose intensiy of encorafenib in the combination.
In the phase 3 COMBI-d and COMBI-v trials, 8, 9, 28 median progression-free survival for dabrafenib-trametinib was 11·0 months (95% CI 8·0-13·9) and 11·4 months (9·9-14·9), respectively. Median progression-free survival for vemurafenib-cobimetinib in the phase 3 coBRIM study was 12·3 months (9·5-13·4). 10 In this study, encorafenib plus binimetinib was associated with a median progression-free survival of 14·9 months (11·0-18·5), the longest median progression-free survival seen to date with any BRAF-MEK inhibitor combination. Additionally, the improved efficacy of encorafenib compared with vemurafenib within this trial supports the hypothesis that extended pathway inhibition can lead to improved clinical outcomes. A direct comparison of encorafenib plus binimetinib with other BRAF-MEK inhibitor combinations would be needed to confirm improved clinical outcomes with encorafenib plus binimetinib.
Although the available BRAF-MEK inhibitor combinations have largely overlapping toxicity profiles, each is associated with a specific toxic effect: pyrexia with dabrafenib-trametinib, and photosensitivity with vemurafenib-cobimetinib. 29, 30 Both of these toxic effects are infrequent with encorafenib plus binimetinib. Pyrexia is the most frequent adverse event with the dabrafenibtrametinib combination (in more than 50% of patients consistently in several studies 9, 11, 17 ) and a leading cause of discontinuation, dose interruption, and dose reduction. 9, 17 Some patients have multiple episodes of pyrexia, with episodes lasting a median duration of 3 days and, in some cases, requiring prophylactic treatment with glucocorticoids. 17 Photo sensitivity reactions are common (seen in 47% of patients) with vemurafenib-cobimetinib. 10, 14, 31 Photo sensitivity is noted as requiring patient education and prospective and ongoing management by patients and clinical staff to mitigate effects. 10 In this study, encorafenib plus binimetinib was associated with all-grade adverse events of interest including pyrexia in 35 (18%) patients and photosensitivity in nine (5%) patients. The features of pyrexia were qualitatively different from those observed with dabrafenib-trametinib, being generally of a lower grade, not recurrent, and most often associated with concurrent illness or progressive disease.
The proportion of patients who had MEK inhibitorrelated toxic effects, including serous retinopathy and left ventricular dysfunction, were largely in line with those observed in other BRAF-MEK inhibitor combination trials in which these effects were actively monitored.
In this trial, the absolute frequency of serous retinopathy in the encorafenib plus binimetinib group was most likely affected by the frequency of monitoring; a high proportion of the events were asymptomatic and detected only through specialised eye examination. The protocolmandated intensity of monitoring for toxic effects to the eye known to be associated with MEK inhibitors in this trial was higher in the encorafenib plus binimetinib group than in the other two groups, which did not include an MEK inhibitor. Since this toxic effect is known to be related to MEK inhibitors, the difference in monitoring schedule probably did not substantially influence the observed difference in the frequency of serous retinopathy across the trial.
This study has several limitations. Few patients had received previous immunotherapy; the ongoing SECOMBIT (NCT02631447), EORTC 1612 (NCT03235245), and IMMU-TARGET (NCT02902042) studies are formally testing the optimal approach for sequencing immunotherapy with ipilimumab-nivolumab or pembrol izumab with encorafenib-binimetinib. These and other studies are anticipated to establish the optimal combinations and sequences of current treatment options that will further improve outcomes for patients with BRAF-mutant melanoma.
Although cross-trial comparisons might be confounded by differences in patient populations, vemurafenib has been a common control across trials for all available BRAF-MEK inhibitor combinations, and its performance in those trials and in this study was similar. Median progressionfree survival was 7·3 months (95% CI 5·8-7·8) in the COMBI-v study and 7·2 months (5·6-7·5) in the coBRIM study, 9, 10, 28 compared with 7·3 months (5·6-8·2) by blinded independent central review and 7·3 months (5·7-8·5) by local review in this study. These results suggest that despite differences in individual baseline prognostic factors (eg, the proportion of patients with increased lactate dehydrogenase concentrations), the populations in these trials are similar with respect to their expected response to treatment. The benefit of encorafenib plus binimetinib will be further defined with longer follow-ups for progression-free survival. Finally, overall survival data, when it becomes available, will provide additional insights into the efficacy of encorafenib plus binimetinib.
In conclusion, results of the COLUMBUS study show that encorafenib plus binimetinib improved progressionfree survival compared with vemurafenib and appears to have an improved tolerability profile compared with encorafenib or vemurafenib. Encorafenib plus binimetinib represents a new treatment option for patients with BRAFmutant melanoma, and further studies investigating the optimal sequence of available treatment modalities are underway.
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